Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
CareDx, Inc CDNA
$7.79
-$0.54 (-6.88%)
На 18:00, 12 мая 2023
+541.85%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
418755150.00000000
-
week52high
27.35
-
week52low
6.22
-
Revenue
321793000
-
P/E TTM
-6
-
Beta
1.03633200
-
EPS
-1.52000000
-
Last Dividend
0.00000000
-
Next Earnings Date
02 авг 2023 г. в 10:59
Описание компании
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Raymond James | Strong Buy | Strong Buy | 10 авг 2022 г. |
| Raymond James | Strong Buy | Strong Buy | 06 мая 2022 г. |
| Stephens & Co. | Overweight | 25 апр 2022 г. | |
| Raymond James | Strong Buy | Strong Buy | 25 февр 2022 г. |
| Raymond James | Strong Buy | Strong Buy | 29 окт 2021 г. |
| Stephens & Co. | Overweight | 02 сент 2022 г. | |
| Raymond James | Strong Buy | Strong Buy | 08 ноя 2022 г. |
| BTIG | Buy | Buy | 07 ноя 2022 г. |
| Goldman Sachs | Buy | Buy | 04 ноя 2022 г. |
| Raymond James | Strong Buy | Strong Buy | 31 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Johnson Alexander L | D | 197169 | 417 | 03 февр 2023 г. |
| Johnson Alexander L | D | 197586 | 417 | 03 февр 2023 г. |
| Seeto Reginald | D | 566103 | 1228 | 03 февр 2023 г. |
| Seeto Reginald | D | 567331 | 1228 | 03 февр 2023 г. |
| Maag Peter | D | 298737 | 5000 | 02 февр 2023 г. |
| Johnson Alexander L | D | 198003 | 2029 | 02 февр 2023 г. |
| Seeto Reginald | D | 568559 | 7244 | 02 февр 2023 г. |
| Seeto Reginald | D | 575803 | 503 | 02 февр 2023 г. |
| Seeto Reginald | D | 576306 | 2316 | 02 февр 2023 г. |
| Ronai Abraham | A | 44100 | 44100 | 01 февр 2023 г. |
Institutional Ownership
Institutional Ownership
| Holder | Shares | Change | Date Reported |
|---|---|---|---|
| ARK Genomic Revolution ETF | 1748640 | 64082 | 31 авг 2020 г. |
| Vanguard Total Stock Market Index Fund | 1341980 | -25725 | 31 авг 2020 г. |
| SPDR S&P Biotech ETF | 1316320 | -67774 | 31 авг 2020 г. |
| iShares Russell 2000 ETF | 917583 | 26296 | 31 авг 2020 г. |
| Alger Small Cap Focus Fund | 4197580 | 0 | 31 июл 2020 г. |
| Invesco Small Cap Growth Fund | 931348 | 0 | 31 июл 2020 г. |
| Invesco Oppenheimer Discovery Fund | 694829 | 10667 | 31 июл 2020 г. |
| Vanguard Extended Market Index Fund | 557047 | -1150 | 31 июл 2020 г. |
| Ivy Small Cap Growth Fund | 1442400 | 0 | 30 июн 2020 г. |
| Credit Suisse (Lux) Digital Health Equity Fund | 1240000 | 0 | 31 янв 2019 г. |
Новостная лента
CareDx to Report First Quarter 2023 Financial Results
Business Wire
08 мая 2023 г. в 07:01
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 10, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The Motley Fool
27 янв 2023 г. в 08:30
The growth-focused money manager is making moves.
Here's Why CareDx (CDNA) Could be Great Choice for a Bottom Fisher
Zacks Investment Research
17 ноя 2022 г. в 11:17
CareDx (CDNA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
CareDx (CDNA) Loses 22.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks Investment Research
11 ноя 2022 г. в 11:18
CareDx (CDNA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
CareDx, Inc. (CDNA) CEO Reg Seeto on Q3 2022 Results - Earnings Call Transcript
Seeking Alpha
03 ноя 2022 г. в 22:52
CareDx, Inc (NASDAQ:CDNA ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Ian Cooney - VP, IR Reg Seeto - CEO Abhishek Jain - Interim CFO Conference Call Participants Brandon Couillard - Jefferies Operator Good day, ladies and gentlemen, and welcome to the CareDx, Incorporated Third Quarter 2022 Earnings Conference Call. Today's conference is being recorded.